gabapentin has been researched along with Injuries, Spinal Cord in 42 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To test the hypotheses that both amitriptyline and gabapentin are more effective in relieving neuropathic pain than an active placebo, diphenhydramine." | 9.12 | Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. ( Courtade, D; Fiess, RN; Holmes, SA; Loubser, PG; Rintala, DH; Tastard, LV, 2007) |
| "Seventy-six per cent of patients receiving gabapentin reported a reduction in neuropathic pain." | 7.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| " We previously reported that once daily treatment with the anti-epileptic and neuropathic pain medication, gabapentin (GBP), at low dosage (50 mg/kg) mitigates experimentally induced AD soon after injections, likely by impeding glutamatergic signaling." | 5.56 | Paradoxical effects of continuous high dose gabapentin treatment on autonomic dysreflexia after complete spinal cord injury. ( Cox, DH; Eldahan, KC; Gollihue, JL; Patel, SP; Rabchevsky, AG; Williams, HC, 2020) |
| "Behavioural assessments of tail muscle spasticity and mean arterial blood pressure responses to noxious somatic and/or visceral stimulation were used to test the effects of GBP on these abnormal reflexes." | 5.37 | Gabapentin for spasticity and autonomic dysreflexia after severe spinal cord injury. ( Duale, H; Kitzman, PH; Lyttle, TS; O'Dell, CR; Patel, SP; Rabchevsky, AG, 2011) |
| "Gabapentin treatment significantly and reversibly changed the responses, consistent with the attenuation of the abnormal sensory behavior, and the attenuated responses lasted for the duration of the drug effect (up to 6 h)." | 5.31 | Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin. ( Hulsebosch, CE; McAdoo, DJ; Perez-Polo, JR; Taylor, CP; Westlund, KN; Xu, GY, 2000) |
| "Hyperhidrosis is a relatively common condition with a multitude of causes." | 5.31 | Hyperhidrosis in pediatric spinal cord injury: a case report and gabapentin therapy. ( Adams, BB; Franz, DN; Kinnett, DG; Vargus-Adams, JN, 2002) |
| "To test the hypotheses that both amitriptyline and gabapentin are more effective in relieving neuropathic pain than an active placebo, diphenhydramine." | 5.12 | Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. ( Courtade, D; Fiess, RN; Holmes, SA; Loubser, PG; Rintala, DH; Tastard, LV, 2007) |
| "Clinicians who prescribe gabapentinoids off-label for pain should be aware of the limited evidence and should acknowledge to patients that potential benefits are uncertain for most off-label uses." | 5.01 | A Clinical Overview of Off-label Use of Gabapentinoid Drugs. ( Brett, AS; Goodman, CW, 2019) |
| " However, when mice are treated early after SCI with human-equivalent doses of the US Food and Drug Administration (FDA)-approved drug gabapentin (GBP), it is possible to block multi-segmental excitatory synaptogenesis and abolish sprouting of autonomic neurons that innervate immune organs and sensory afferents that trigger pain and autonomic dysreflexia (AD)." | 4.02 | Acute post-injury blockade of α2δ-1 calcium channel subunits prevents pathological autonomic plasticity after spinal cord injury. ( Brennan, FH; Davis, H; Eroglu, C; Ferguson, AR; Guan, Z; Harris, C; Mo, X; Noble, BT; Popovich, PG; Wang, Y, 2021) |
| "The 5-HT re-uptake inhibitor fluoxetine (3-30 mg/kg), the NA re-uptake inhibitor reboxetine (3-30 mg/kg), the dual 5-HT and NA re-uptake inhibitor venlafaxine (3-100 mg/kg) and the dual DA and NA re-uptake inhibitor bupropion (3-30 mg/kg) were tested after intraperitoneal administration in rat models of acute, persistent and neuropathic pain." | 3.73 | Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain. ( Blackburn-Munro, G; Nielsen, AN; Pedersen, LH, 2005) |
| "Seventy-six per cent of patients receiving gabapentin reported a reduction in neuropathic pain." | 3.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "Gabapentin is a new antiepileptic drug that may additionally have a role in the treatment of neuropathic pain." | 2.71 | Gabapentin effect on neuropathic pain compared among patients with spinal cord injury and different durations of symptoms. ( Ahn, SH; Bae, JH; Jang, SH; Lee, BS; Moon, HW; Park, HW; Sakong, J, 2003) |
| " This was followed by a 4-week stable dosing period when the patients continued to receive maximum tolerated doses, a 2-week washout period, then a crossover of 4 weeks of medication/placebo titration, and another 4 weeks of stable dosing period." | 2.71 | Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. ( Levendoglu, F; Ogün, CO; Ogün, TC; Ozerbil, O; Ugurlu, H, 2004) |
| " No significant difference was found among other pain descriptors during the gabapentin and placebo treatment, although this may have been limited by the small sample size and low maximum dosage of gabapentin." | 2.70 | Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. ( Chen, B; DeLisa, JA; Johnston, M; Kirshblum, S; Millis, S; Tai, Q, 2002) |
| "Gabapentin or placebo was given orally in doses 400 mg three times daily for 48 h." | 2.68 | Effectiveness of gabapentin in controlling spasticity: a quantitative study. ( Graves, DE; Mueller, M; Olson, WH; Priebe, MM; Sherwood, AM, 1997) |
| "As some patients with spasticity are either refractory to or intolerant of established medical treatments, we conducted this study to investigate the effect of gabapentin on spasticity in patients with spinal cord injury." | 2.68 | Gabapentin for the treatment of spasticity in patients with spinal cord injury. ( Gruenthal, M; Mueller, M; Olson, WH; Olson, WL; Priebe, MM; Sherwood, AM, 1997) |
| " On the other hand, for GP a maximum dosage of 3,600 mg/day reduced VAS score (P = 0." | 2.44 | Efficacy of pregabalin and gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature. ( Amaniti, E; Kouvelas, D; Papazisis, G; Tzellos, TG, 2008) |
| "127 patients, aged 18-70 years, who had neuropathic pain related to spinal cord injury (SCI) and disease duration of at least 12 months." | 1.91 | Misuse of gabapentinoids (pregabalin and gabapentin) in patients with neuropathic pain related to spinal cord injury. ( Akıncı, MG; Altas, EU; Konak, HE; Onat, SS; Polat, CS, 2023) |
| "Spinal cord injury (SCI)-induced neuropathic pain (SCI-NP) develops in up to 60 to 70% of people affected by traumatic SCI, leading to a major decline in quality of life and increased risk for depression, anxiety, and addiction." | 1.91 | Inhibition of T-Type Calcium Channels With TTA-P2 Reduces Chronic Neuropathic Pain Following Spinal Cord Injury in Rats. ( Gunaratna, K; Kaczocha, M; Lauzadis, J; Liu, H; Puopolo, M; Sipple, E, 2023) |
| " We previously reported that once daily treatment with the anti-epileptic and neuropathic pain medication, gabapentin (GBP), at low dosage (50 mg/kg) mitigates experimentally induced AD soon after injections, likely by impeding glutamatergic signaling." | 1.56 | Paradoxical effects of continuous high dose gabapentin treatment on autonomic dysreflexia after complete spinal cord injury. ( Cox, DH; Eldahan, KC; Gollihue, JL; Patel, SP; Rabchevsky, AG; Williams, HC, 2020) |
| "Sleep quality, chronotype, daytime sleepiness, neuropathic pain severity and interference were assessed based on questionnaires." | 1.51 | Actigraphy-based evaluation of sleep quality and physical activity in individuals with spinal cord injury. ( Albu, S; Forner-Cordero, A; Umemura, G, 2019) |
| "Sinomenine can enhance the efficacy of gabapentin or ligustrazine hydrochloride in rodent models of peripheral or central neuropathic pain, without introducing tolerance or other notable side effects." | 1.51 | Sinomenine facilitates the efficacy of gabapentin or ligustrazine hydrochloride in animal models of neuropathic pain. ( Gao, T; Jiang, JD; Li, T; Shi, T; Wiesenfeld-Hallin, Z; Xu, XJ, 2019) |
| "Behavioural assessments of tail muscle spasticity and mean arterial blood pressure responses to noxious somatic and/or visceral stimulation were used to test the effects of GBP on these abnormal reflexes." | 1.37 | Gabapentin for spasticity and autonomic dysreflexia after severe spinal cord injury. ( Duale, H; Kitzman, PH; Lyttle, TS; O'Dell, CR; Patel, SP; Rabchevsky, AG, 2011) |
| "Accordingly, we hypothesized that tactile allodynia post SCI is mediated by an upregulation of Ca(v)α2δ-1 in dorsal spinal cord." | 1.37 | Calcium channel alpha-2-delta-1 protein upregulation in dorsal spinal cord mediates spinal cord injury-induced neuropathic pain states. ( Boroujerdi, A; Kim, D; Luo, DZ; Sharp, K; Steward, O; Zeng, J, 2011) |
| "Mechanical hyperalgesia was fully reversed by three analgesic drugs used in treating neuropathic SCI pain, but their duration of action differed significantly, showing a rank order of amitriptyline (24-48 h)≫morphine (6 h)>gabapentin (2 h)." | 1.36 | Above-level mechanical hyperalgesia in rats develops after incomplete spinal cord injury but not after cord transection, and is reversed by amitriptyline, morphine and gabapentin. ( Densmore, VS; Kalous, A; Keast, JR; Osborne, PB, 2010) |
| "Both spastic behavior and electromyography (EMG) activity were significantly decreased at 1 and 3 h post-GBP injection when compared with the activity level following administration of saline." | 1.34 | Gabapentin suppresses spasticity in the spinal cord-injured rat. ( Dwyer, MK; Kitzman, PH; Uhl, TL, 2007) |
| "Gabapentin treatment significantly and reversibly changed the responses, consistent with the attenuation of the abnormal sensory behavior, and the attenuated responses lasted for the duration of the drug effect (up to 6 h)." | 1.31 | Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin. ( Hulsebosch, CE; McAdoo, DJ; Perez-Polo, JR; Taylor, CP; Westlund, KN; Xu, GY, 2000) |
| "SCI gabapentin-treated rats did not display differences in total rearing time until PSD 28 and a significant difference in total activity of all measured parameters was not seen until PSD 60." | 1.31 | Changes in exploratory behavior as a measure of chronic central pain following spinal cord injury. ( Grady, JJ; Hulsebosch, CE; Mills, CD, 2001) |
| "Hyperhidrosis is a relatively common condition with a multitude of causes." | 1.31 | Hyperhidrosis in pediatric spinal cord injury: a case report and gabapentin therapy. ( Adams, BB; Franz, DN; Kinnett, DG; Vargus-Adams, JN, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (7.14) | 18.2507 |
| 2000's | 17 (40.48) | 29.6817 |
| 2010's | 16 (38.10) | 24.3611 |
| 2020's | 6 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Polat, CS | 1 |
| Konak, HE | 1 |
| Akıncı, MG | 1 |
| Onat, SS | 1 |
| Altas, EU | 1 |
| Asgardoon, MH | 1 |
| Jazayeri, SB | 1 |
| Behkar, A | 1 |
| Dabbagh Ohadi, MA | 1 |
| Yarmohammadi, H | 1 |
| Ghodsi, Z | 1 |
| Pomerani, TI | 1 |
| Mojtahedzadeh, M | 1 |
| Rahimi-Movaghar, V | 1 |
| Liu, H | 1 |
| Lauzadis, J | 1 |
| Gunaratna, K | 1 |
| Sipple, E | 1 |
| Kaczocha, M | 1 |
| Puopolo, M | 1 |
| Eldahan, KC | 1 |
| Williams, HC | 1 |
| Cox, DH | 1 |
| Gollihue, JL | 1 |
| Patel, SP | 2 |
| Rabchevsky, AG | 2 |
| Cragg, JJ | 1 |
| Jutzeler, CR | 1 |
| Grassner, L | 1 |
| Ramer, M | 1 |
| Bradke, F | 1 |
| Kramer, JLK | 1 |
| Brennan, FH | 1 |
| Noble, BT | 1 |
| Wang, Y | 1 |
| Guan, Z | 1 |
| Davis, H | 1 |
| Mo, X | 1 |
| Harris, C | 1 |
| Eroglu, C | 1 |
| Ferguson, AR | 1 |
| Popovich, PG | 1 |
| Louis, JV | 1 |
| Lu, Y | 1 |
| Pieschl, R | 1 |
| Tian, Y | 1 |
| Hong, Y | 1 |
| Dandapani, K | 1 |
| Naidu, S | 1 |
| Vikramadithyan, RK | 1 |
| Dzierba, C | 1 |
| Sarvasiddhi, SK | 1 |
| Nara, SJ | 1 |
| Bronson, J | 1 |
| Macor, JE | 1 |
| Albright, C | 1 |
| Kostich, W | 1 |
| Li, YW | 1 |
| Hamdaoui, M | 1 |
| Ruppert, E | 1 |
| Comtet, H | 1 |
| Kilic-Huck, U | 1 |
| Wolff, V | 1 |
| Bataillard, M | 1 |
| Bourgin, P | 1 |
| McKinley, EC | 1 |
| Richardson, EJ | 1 |
| McGwin, G | 1 |
| Zhang, J | 1 |
| Shi, T | 2 |
| Hao, JX | 3 |
| Wiesenfeld-Hallin, Z | 4 |
| Xu, XJ | 4 |
| Albu, S | 1 |
| Umemura, G | 1 |
| Forner-Cordero, A | 1 |
| Goodman, CW | 1 |
| Brett, AS | 1 |
| Gao, T | 1 |
| Li, T | 1 |
| Jiang, JD | 1 |
| Guy, S | 1 |
| Mehta, S | 2 |
| Leff, L | 1 |
| Teasell, R | 1 |
| Loh, E | 2 |
| McIntyre, A | 1 |
| Dijkers, M | 1 |
| Teasell, RW | 1 |
| Lee-Kubli, CA | 1 |
| Ingves, M | 1 |
| Henry, KW | 1 |
| Shiao, R | 1 |
| Collyer, E | 1 |
| Tuszynski, MH | 1 |
| Campana, WM | 1 |
| Tzellos, TG | 1 |
| Papazisis, G | 1 |
| Amaniti, E | 1 |
| Kouvelas, D | 1 |
| Tanabe, M | 1 |
| Ono, K | 1 |
| Honda, M | 1 |
| Ono, H | 1 |
| Duale, H | 1 |
| Lyttle, TS | 1 |
| O'Dell, CR | 1 |
| Kitzman, PH | 2 |
| Densmore, VS | 1 |
| Kalous, A | 1 |
| Keast, JR | 1 |
| Osborne, PB | 1 |
| Emmez, H | 1 |
| Börcek, AÖ | 1 |
| Kaymaz, M | 1 |
| Kaymaz, F | 1 |
| Durdağ, E | 1 |
| Civi, S | 1 |
| Gülbahar, O | 1 |
| Aykol, S | 1 |
| Paşaoğlu, A | 1 |
| Boroujerdi, A | 1 |
| Zeng, J | 1 |
| Sharp, K | 1 |
| Kim, D | 1 |
| Steward, O | 1 |
| Luo, DZ | 1 |
| Hey, M | 1 |
| Wilson, I | 1 |
| Johnson, MI | 1 |
| Singh, H | 1 |
| Wang, MY | 1 |
| Tai, Q | 1 |
| Kirshblum, S | 1 |
| Chen, B | 1 |
| Millis, S | 1 |
| Johnston, M | 1 |
| DeLisa, JA | 1 |
| Vogel, LC | 1 |
| Anderson, CJ | 1 |
| Ahn, SH | 1 |
| Park, HW | 1 |
| Lee, BS | 1 |
| Moon, HW | 1 |
| Jang, SH | 1 |
| Sakong, J | 1 |
| Bae, JH | 1 |
| Hwang, W | 1 |
| Ralph, J | 1 |
| Marco, E | 1 |
| Hemphill, JC | 1 |
| Wu, WP | 1 |
| Ongini, E | 1 |
| Impagnatiello, F | 1 |
| Presotto, C | 1 |
| Levendoglu, F | 1 |
| Ogün, CO | 1 |
| Ozerbil, O | 1 |
| Ogün, TC | 1 |
| Ugurlu, H | 1 |
| Pedersen, LH | 1 |
| Nielsen, AN | 1 |
| Blackburn-Munro, G | 1 |
| Uhl, TL | 1 |
| Dwyer, MK | 1 |
| Rintala, DH | 1 |
| Holmes, SA | 1 |
| Courtade, D | 1 |
| Fiess, RN | 1 |
| Tastard, LV | 1 |
| Loubser, PG | 1 |
| Priebe, MM | 2 |
| Sherwood, AM | 2 |
| Graves, DE | 1 |
| Mueller, M | 2 |
| Olson, WH | 2 |
| Gruenthal, M | 1 |
| Olson, WL | 1 |
| Ness, TJ | 1 |
| San Pedro, EC | 1 |
| Richards, SJ | 1 |
| Kezar, L | 1 |
| Liu, HG | 1 |
| Mountz, JM | 1 |
| Urban, L | 1 |
| Kapadia, NP | 1 |
| Harden, N | 1 |
| Hulsebosch, CE | 2 |
| Xu, GY | 1 |
| Perez-Polo, JR | 1 |
| Westlund, KN | 1 |
| Taylor, CP | 1 |
| McAdoo, DJ | 1 |
| Mills, CD | 1 |
| Grady, JJ | 1 |
| Adams, BB | 1 |
| Vargus-Adams, JN | 1 |
| Franz, DN | 1 |
| Kinnett, DG | 1 |
| To, TP | 1 |
| Lim, TC | 1 |
| Hill, ST | 1 |
| Frauman, AG | 1 |
| Cooper, N | 1 |
| Kirsa, SW | 1 |
| Brown, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Subcutaneous Injection of Botulinum Toxin A for At--Level Back Pain in Patients With Spinal Cord Injury[NCT02736890] | Phase 2 | 8 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to funding not available to continue) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Mean change from baseline. Participants are asked Taking into account your pain level and how it affects your life, are you feeling better, the same or worse than when you started treatment? and then to quantify the magnitude of the change. with the 7-Point guy Farrar which measures the global treatment effect from with scale from 0 to 6, higher score indicates worse outcomes." (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 2.2 | 2.4 | 2 | 2 | 0 | 0 | 0 | 0 |
| Placebo Then Botulinum Toxin A | 0.3 | 0.3 | 0 | 0 | 5 | 5 | 3 | 1 |
The International Basic Pain Dataset is an assessment tool which includes several components including: location of pain, temporal qualities of the pain, type of pain, pain interference measures of activity, sleep, and mood. It has been shown to be valid in an interview/self -report format. The pain affecting day-to-day activities subset of the dataset is scored is from 0 to 10, with higher score indicating less favorable outcomes. (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 4.2 | 5.4 | 5 | 5 | 4.8 | 7 | 6.7 | 7 | 6.7 |
| Placebo Then Botulinum Toxin A | 5.3 | 2.7 | 2.7 | 2.7 | 2.7 | 2 | 3 | 4 | 5 |
The International Basic Pain Dataset is an assessment tool which includes several components including: location of pain, temporal qualities of the pain, type of pain, pain interference measures of activity, sleep, and mood. It has been shown to be valid in an interview/self -report format. The pain affecting mood subset of the dataset is scored is from 0 to 10, with higher score indicating less favorable outcomes. (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 5.6 | 6.6 | 5.8 | 5.2 | 5.6 | 7 | 7 | 7.3 | 6.7 |
| Placebo Then Botulinum Toxin A | 5.7 | 2.7 | 2.7 | 4.3 | 5.7 | 2 | 3 | 4 | 7 |
The International Basic Pain Dataset is an assessment tool which includes several components including: location of pain, temporal qualities of the pain, type of pain, pain interference measures of activity, sleep, and mood. It has been shown to be valid in an interview/self -report format. The pain affecting sleep subset of the dataset is scored is from 0 to 10, with higher score indicating less favorable outcomes. (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 5.8 | 4.6 | 5 | 6 | 6.2 | 8 | 8 | 8 | 7.3 |
| Placebo Then Botulinum Toxin A | 6.7 | 4.7 | 3.3 | 6 | 6.7 | 1 | 3 | 4 | 5 |
Participant rated pain intensity from 0-10, with higher score indicating more pain (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | score on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 7.6 | 6.4 | 5.6 | 5.6 | 5.6 | 8 | 8 | 6.7 | 8 |
| Placebo Then Botulinum Toxin A | 8 | 8 | 8 | 8 | 8 | 5 | 5 | 6 | 7 |
PGI measures activity affected by pain. Full score is 0 to 10000, with higher score indicating better function (NCT02736890)
Timeframe: up to 12 weeks post-injection, for a total of 24 weeks from baseline
| Intervention | score on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 2 week post injection | 4 week post injection | 8 week post injection | 12 week post injection | crossover 2 week follow up | crossover 4 week follow up | crossover 8 week follow up | crossover 12 week follow up | |
| Botulinum Toxin A Then Placebo | 4250 | 5240 | 5219 | 3725 | 4330 | 3333.3 | 3333.3 | 3333.3 | 3333.3 |
| Placebo Then Botulinum Toxin A | 1500 | 1550 | 1825 | 2800 | 1800 | 3500 | 3750 | 3000 | 1500 |
7 reviews available for gabapentin and Injuries, Spinal Cord
| Article | Year |
|---|---|
Pharmacologic therapies of pain in patients with spinal cord injury: a systematic review.
Topics: Amitriptyline; Anticonvulsants; Gabapentin; Humans; Ketamine; Pain; Pregabalin; Spinal Cord Injuries | 2022 |
Beneficial "Pharmaceutical Pleiotropy" of Gabapentinoids in Spinal Cord Injury: A Case for Refining Standard-of-Care.
Topics: Analgesics; Animals; Gabapentin; Humans; Neuralgia; Pregabalin; Spinal Cord Injuries | 2020 |
A Clinical Overview of Off-label Use of Gabapentinoid Drugs.
Topics: Analgesics; Diabetic Neuropathies; Drug Approval; Fibromyalgia; Gabapentin; Humans; Low Back Pain; M | 2019 |
Anticonvulsant medication use for the management of pain following spinal cord injury: systematic review and effectiveness analysis.
Topics: Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2014 |
Gabapentinoids are effective in decreasing neuropathic pain and other secondary outcomes after spinal cord injury: a meta-analysis.
Topics: Amines; Analgesics; Anxiety; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Depression; Gaba | 2014 |
Efficacy of pregabalin and gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gamma-Aminobut | 2008 |
Gabapentin reduces experimental secondary neurologic dysfunction in rats.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Nervous S | 2011 |
6 trials available for gabapentin and Injuries, Spinal Cord
| Article | Year |
|---|---|
Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial.
Topics: Acetates; Adult; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dose-Response | 2002 |
Gabapentin effect on neuropathic pain compared among patients with spinal cord injury and different durations of symptoms.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Ac | 2003 |
Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury.
Topics: Acetates; Adult; Aged; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Disabili | 2004 |
Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury.
Topics: Adult; Aged; Amines; Amitriptyline; Analgesics; Analysis of Variance; Antidepressive Agents, Tricycl | 2007 |
Effectiveness of gabapentin in controlling spasticity: a quantitative study.
Topics: Acetates; Adult; Amines; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dose-Response Relationship | 1997 |
Gabapentin for the treatment of spasticity in patients with spinal cord injury.
Topics: Acetates; Administration, Oral; Adult; Amines; Anticonvulsants; Cross-Over Studies; Cyclohexanecarbo | 1997 |
29 other studies available for gabapentin and Injuries, Spinal Cord
| Article | Year |
|---|---|
Misuse of gabapentinoids (pregabalin and gabapentin) in patients with neuropathic pain related to spinal cord injury.
Topics: Amines; Analgesics; Cross-Sectional Studies; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobut | 2023 |
Inhibition of T-Type Calcium Channels With TTA-P2 Reduces Chronic Neuropathic Pain Following Spinal Cord Injury in Rats.
Topics: Animals; Calcium Channels, T-Type; Female; Gabapentin; Male; Neuralgia; Quality of Life; Rats; Rats, | 2023 |
Paradoxical effects of continuous high dose gabapentin treatment on autonomic dysreflexia after complete spinal cord injury.
Topics: Animals; Autonomic Dysreflexia; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; | 2020 |
Acute post-injury blockade of α2δ-1 calcium channel subunits prevents pathological autonomic plasticity after spinal cord injury.
Topics: Animals; Autonomic Dysreflexia; Calcium Channel Blockers; Excitatory Amino Acid Antagonists; Gabapen | 2021 |
[
Topics: Amines; Animals; Autoradiography; Brain; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-R | 2017 |
Restless legs syndrome related to hemorrhage of a thoracic spinal cord cavernoma.
Topics: Female; Gabapentin; Hemorrhage; Humans; Magnetic Resonance Imaging; Middle Aged; Polysomnography; Re | 2018 |
Evaluating the effectiveness of antidepressant therapy adjuvant to gabapentin and pregabalin for treatment of SCI-related neuropathic pain.
Topics: Adult; Analgesics; Antidepressive Agents; Chemotherapy, Adjuvant; Cohort Studies; Drug Therapy, Comb | 2018 |
Gabapentin and NMDA receptor antagonists interacts synergistically to alleviate allodynia in two rat models of neuropathic pain.
Topics: Animals; Behavior, Animal; Dextromethorphan; Dizocilpine Maleate; Dose-Response Relationship, Drug; | 2018 |
Actigraphy-based evaluation of sleep quality and physical activity in individuals with spinal cord injury.
Topics: Actigraphy; Adult; Analgesics; Benzodiazepines; Case-Control Studies; Exercise; Female; Gabapentin; | 2019 |
Sinomenine facilitates the efficacy of gabapentin or ligustrazine hydrochloride in animal models of neuropathic pain.
Topics: Analgesics; Animals; Disease Models, Animal; Drug Synergism; Gabapentin; Male; Mice; Mice, Inbred C5 | 2019 |
Analysis of the behavioral, cellular and molecular characteristics of pain in severe rodent spinal cord injury.
Topics: Amines; Animals; Calcitonin Gene-Related Peptide; Calcium-Binding Proteins; Carbenoxolone; Connexin | 2016 |
Gabapentin and pregabalin ameliorate mechanical hypersensitivity after spinal cord injury in mice.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Drug Eva | 2009 |
Gabapentin for spasticity and autonomic dysreflexia after severe spinal cord injury.
Topics: Amines; Animals; Autonomic Dysreflexia; Cyclohexanecarboxylic Acids; Disease Models, Animal; Female; | 2011 |
Above-level mechanical hyperalgesia in rats develops after incomplete spinal cord injury but not after cord transection, and is reversed by amitriptyline, morphine and gabapentin.
Topics: Amines; Amitriptyline; Analgesics; Animals; Cell Count; Cross-Over Studies; Cyclohexanecarboxylic Ac | 2010 |
Neuroprotective effects of gabapentin in experimental spinal cord injury.
Topics: Amines; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cyclohexanecarboxylic Acids; Di | 2010 |
Calcium channel alpha-2-delta-1 protein upregulation in dorsal spinal cord mediates spinal cord injury-induced neuropathic pain states.
Topics: Amines; Analgesics; Animals; Calcium Channels; Calcium Channels, L-Type; Cyclohexanecarboxylic Acids | 2011 |
Stellate ganglion blockade (SGB) for refractory index finger pain - a case report.
Topics: Abdominal Pain; Accidental Falls; Acetaminophen; Adult; Amines; Autonomic Nerve Block; Chronic Disea | 2011 |
Self-injurious behavior in children and adolescents with spinal cord injuries.
Topics: Acetates; Adolescent; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Fe | 2002 |
Incomplete Brown-Séquard syndrome after methamphetamine injection into the neck.
Topics: Acetates; Adult; Amines; Brown-Sequard Syndrome; Causalgia; Cyclohexanecarboxylic Acids; Gabapentin; | 2003 |
A nitric oxide (NO)-releasing derivative of gabapentin, NCX 8001, alleviates neuropathic pain-like behavior after spinal cord and peripheral nerve injury.
Topics: Acetates; Amines; Animals; Aorta, Thoracic; Behavior, Animal; Cyclic GMP; Cyclohexanecarboxylic Acid | 2004 |
Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain.
Topics: Amines; Analgesics; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Bupropio | 2005 |
Gabapentin suppresses spasticity in the spinal cord-injured rat.
Topics: Amines; Analysis of Variance; Animals; Anticonvulsants; Behavior, Animal; Cross-Over Studies; Cycloh | 2007 |
A case of spinal cord injury-related pain with baseline rCBF brain SPECT imaging and beneficial response to gabapentin.
Topics: Acetates; Adult; Amines; Analgesics; Brain; Cerebrovascular Circulation; Cyclohexanecarboxylic Acids | 1998 |
Repeated administration of systemic gabapentin alleviates allodynia-like behaviors in spinally injured rats.
Topics: Acetates; Amines; Analgesics; Animals; Cold Temperature; Cyclohexanecarboxylic Acids; Drug Administr | 2000 |
Gabapentin for chronic pain in spinal cord injury: a case report.
Topics: Acetates; Adult; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Female; Gabapenti | 2000 |
Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin.
Topics: Acetates; Amines; Analgesics; Animals; Behavior, Animal; Chronic Disease; Contusions; Cyclohexanecar | 2000 |
Changes in exploratory behavior as a measure of chronic central pain following spinal cord injury.
Topics: Acetates; Amines; Analgesics; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Exploratory Beh | 2001 |
Hyperhidrosis in pediatric spinal cord injury: a case report and gabapentin therapy.
Topics: Acetates; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami | 2002 |
Gabapentin for neuropathic pain following spinal cord injury.
Topics: Acetates; Acute Disease; Adolescent; Adult; Aged; Amines; Chronic Disease; Cyclohexanecarboxylic Aci | 2002 |